10-K: Ligand Pharma's Royalty Model Drives 60% Revenue Growth

Ligand Pharmaceuticals reports significant revenue growth in 2025, driven by its biopharmaceutical royalty aggregation strategy and key product performance, alongside strategic investments and a strong cash position.

Summary

• Total revenue and income increased by $101.0 million, or 60%, to $268.1 million in 2025 compared to $167.1 million in 2024.
• Royalties increased by $52.2 million, or 48%, primarily due to income from the Qarziba financial royalty asset and increased sales of Filspari, Ohtuvayre, and Capvaxive.
• Captisol sales increased by $9.3 million to $40.2 million in 2025, representing a 30% increase.
• Contract revenue and income increased by $39.4 million (143%), mainly due to $53.1 million income from the Pelthos Transaction.
• Net income from continuing operations was $124.5 million in 2025, a significant improvement from a net loss of $4.0 million in 2024.
• Cash, cash equivalents, and short-term investments increased by $477.4 million to $733.5 million as of December 31, 2025.
• Issued $460 million in 0.75% convertible senior notes due 2030, with net proceeds of approximately $445.1 million.
• Made strategic investments in 2025, including $50 million in Castle Creek Biosciences for D-Fi, $25 million in Orchestra BioMed for cardiology programs, and $7 million in Arecor Limited for AT220 and AT292.
• Completed the Pelthos Transaction, divesting LNHC, Inc. and retaining a 48% equity interest in Pelthos Therapeutics Inc., along with a 13% royalty on Zelsuvmi worldwide sales.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, with significant revenue and net income growth, robust cash generation, and successful execution of its royalty aggregation strategy. While some product royalties declined and R&D expenses increased, the overall financial health and strategic positioning appear solid.

Positives

• Total revenue and income increased by $101.0 million, or 60%, to $268.1 million in 2025 compared to $167.1 million in 2024.
• Royalties increased by $52.2 million, or 48%, primarily due to income from the Qarziba financial royalty asset and increased sales of Filspari, Ohtuvayre, and Capvaxive.
• Net income from continuing operations was $124.5 million in 2025, a significant improvement from a net loss of $4.0 million in 2024.
• Cash, cash equivalents, and short-term investments increased by $477.4 million to $733.5 million, indicating a strong liquidity position.
• The Pelthos Transaction generated $53.1 million in income and secured a 13% royalty on Zelsuvmi worldwide sales, following its commercial launch.
• Positive Phase 3 results for Qtorin rapamycin (Palvella) for Microcystic LM, with NDA submission planned for the second half of 2026.
• FDA approval of Capvaxive in June 2024 triggered a $2 million milestone payment and a low single-digit royalty.
• FDA approval of Ohtuvayre in June 2024, with a 3% royalty on global net sales.
• Tzield received FDA approval in November 2022, China NMPA approval in September 2025, and European Commission approval in January 2026, expanding its market reach.
• The company's internal control over financial reporting was deemed effective as of December 31, 2025.

Negatives

• Kyprolis royalty receipts decreased from $38.4 million in 2024 to $35.5 million in 2025.
• Evomela royalty receipts decreased from $8.7 million in 2024 to $5.9 million in 2025, with generic competition expected from June 1, 2026.
• Amgen settled patent litigation for Kyprolis, with a generic product launch publicly reported for 2027 or sooner.
• Financial royalty asset impairment of $6.2 million in 2025, primarily due to UGN-301 and other Agenus partner programs.
• Takeda discontinued its soticlestat program in January 2025, leading to a full impairment of the related financial royalty asset in 2024.
• Nuance Pharma disputed Verona's (now Merck's) buy-back notice for Ohtuvayre rights in certain Asian territories.
• Increased R&D expenses by $59.8 million in 2025, primarily due to funding arrangements for D-Fi ($44.3 million) and Orchestra ($17.8 million).
• Increased general and administrative expenses by $13.8 million in 2025, primarily due to transaction costs.
• Significant decrease in gain from short-term investments ($18.4 million in 2025 vs. $75.0 million in 2024), mainly due to no Viking common stock sales in 2025 compared to a $60.0 million realized gain in 2024.
• Recorded an unrealized loss on Viking common stock of $5.1 million in 2025 compared to a $9.0 million unrealized gain in 2024.
• Ongoing legal proceedings against Bexson Biomedical and generic drug companies (PH Health Ltd., Par Health USA, Endo USA, Inc., Endo Operations Limited, and Endo, Inc.) regarding patent infringement.

Risks

• The ability to collect future revenue from collaboration partners, Captisol material sales, and licensing relationships is not guaranteed.
• Captisol supply from the sole supplier (Hovione) may be impacted by interruptions, potentially affecting revenue and customer relationships.
• The success of partnered programs could be adversely affected by changes in collaboration partners' strategy or focus, development or regulatory hurdles, and market acceptance.
• The biopharmaceutical product market faces general risks, including changes in growth rate, competition from new technologies, and other sales risks.
• Limited information about acquired biopharmaceutical products and underlying assumptions regarding future cash flow and revenue generation may prove inaccurate.
• Collaboration partners may become insolvent, delaying or impeding royalty payments.
• Third-party intellectual property rights may prevent the company or its partners from developing products, and intellectual property issues can be expensive and time-consuming to resolve.
• Risks related to obtaining and maintaining sufficient intellectual property protection for products, platforms, and technology.
• The validity, scope, and enforceability of the company's and its collaboration partners' patents and other intellectual property may be challenged.
• Market acceptance and sales of any approved product depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures (e.g., ACA, IRA, OBBBA).
• Regulatory approval of product candidates is lengthy, time-consuming, and inherently unpredictable, and is not guaranteed.
• Risks related to compliance with healthcare, environmental, and other applicable laws and regulations.
• Difficulties from strategic acquisitions and other M&A transactions could adversely affect stock price, operating results, and financial condition.
• Continued exposure to risks related to Pelthos due to ongoing equity ownership and other investments.
• Operating results may fluctuate significantly, making future operating results difficult to predict and potentially causing them to fall below expectations.
• Changes or modifications in financial accounting standards or tax laws may harm results of operations.
• Cybersecurity incidents could compromise sensitive data and interrupt operations, leading to regulatory enforcement and reputational harm.
• Ineffective development or deployment of artificial intelligence (AI) technologies could lead to errors or disruptions, and evolving AI regulations could impose additional compliance burdens.
• Product liability lawsuits against the company or its partners could result in substantial liabilities and require limiting commercialization.
• Risks related to handling hazardous materials and other regulations governing environmental safety.
• The terms of the Credit Agreement may limit operational flexibility and adversely affect financial health and competitive position.
• The use of debt magnifies the potential for loss if acquired royalties do not generate sufficient income.
• The ability to satisfy debt obligations depends on future performance, which is subject to economic, financial, competitive, and other factors beyond control.
• Conversion of the 2030 Notes could dilute the ownership interest of existing stockholders or depress the stock price.
• The Credit Agreement limits the ability to pay any cash amount upon the conversion or repurchase of the 2030 Notes.
• Impairment charges pertaining to goodwill, identifiable intangible assets, or other long-lived assets from mergers and acquisitions could adversely impact results of operations.
• Investments are subject to market and credit risks that could diminish their value, especially during periods of extreme volatility.
• The company could be determined to be an investment company under the U.S. Investment Company Act of 1940, which could make it impractical to continue business as contemplated.
• Charter documents and concentration of ownership may hinder or prevent change of control transactions.
• The stock price has been volatile and could experience a sudden decline in value.
• Unfavorable global economic and political conditions could adversely affect business, financial condition, or results of operations.
• Business is subject to risks arising from pandemic and epidemic diseases, which could disrupt operations and impact revenues.
• If securities or industry analysts do not publish research reports or make adverse recommendations, the stock price and trading volume may decline.
• The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of royalties.
• Legal claims and proceedings could adversely affect the business.

Future Outlook

The company expects to continue refining its Environmental, Health, and Safety (EHS) policies and practices in 2026 and maintain proactive shareholder and employee engagement. Key product developments include an NDA submission for Qtorin rapamycin planned for the second half of 2026, and a PDUFA target action date of April 13, 2026, for Filspari's sNDA for FSGS. Results from the Qarziba BEACON-2 trial are anticipated in 2028, and data from the Lasofoxifene Phase 3 ELAINE-3 trial are expected in mid-2027. The company believes its current financial resources are adequate to support ongoing operations, R&D, potential stock repurchases, and future strategic investments and acquisitions.

Management Comments

• Our primary business is investing in and structuring royalty interests in midto late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.
• Our goal is to provide investors with exposure to biopharmaceutical innovation through a diversified portfolio of royalty interests while mitigating the binary risk and capital intensity traditionally associated with drug development.
• Since refocusing the business in 2022, we have built a highly experienced business and investment team to execute our strategy.
• We believe our business model is highly scalable and has significant growth potential.
• We believe our focused approach enhances the durability of our business and supports our long-term growth objectives.
• We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed.
• We believe we maintain adequate inventory of Captisol to meet our current partner needs and that our Captisol capacity will be sufficient to meet future partner needs.
• We are committed to providing a safe and healthy workplace, promoting environmental excellence in our communities, and complying with all relevant regulations and industry standards.
• We believe that our business benefits from the different perspectives a diverse workforce brings.
• We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization.
• We currently believe that none of the claims or actions pending against us is likely to have, individually or in aggregate, a material adverse effect on our business, financial condition or results of operations.
• We believe that our existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; continued advancement of research and development efforts; potential stock repurchases; and other business initiatives we plan to strategically pursue, including acquisitions and strategic investments.
• We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly.
• We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value.
• We do not intend to sell these securities and it is unlikely that we will be required to sell these securities before the recovery of the amortized cost basis as of December 31, 2025.

Industry Context

StockSavvy.ai notes that Ligand's strategy of aggregating royalty interests in midto late-stage biopharmaceutical products positions it uniquely in the industry, mitigating the high binary risk associated with traditional drug development. The focus on infrastructure-light platform technologies like Captisol and NITRICIL aligns with a trend towards specialized, high-margin business models in biotech, contrasting with capital-intensive R&D. The increasing demand for structured capital in the biopharmaceutical market creates significant investment opportunities for royalty aggregators like Ligand. The industry is also seeing increased regulatory scrutiny on drug pricing (e.g., IRA) and evolving data privacy laws, which could impact all players, including Ligand's partners.

Comparison to Industry Standards

• Ligand's 60% revenue growth in FY2025 significantly outpaces the Nasdaq Biotechnology Index's 31.26% return for the same period (12/31/2024 to 12/31/2025), indicating strong outperformance relative to the broader biotech market.
• The company's strategic pivot to an "infrastructure-light, high-margin" royalty aggregation model differentiates it from traditional, vertically integrated pharmaceutical companies like Amgen or Merck, which typically incur higher fixed costs and R&D intensity.
• The diversification across 12 major commercial-stage royalty assets and over 90 development-stage programs provides a risk mitigation profile distinct from single-asset biotech companies, offering more predictable cash flows compared to the binary outcomes common in drug development.
• The successful commercial launch of Zelsuvmi (Pelthos) as the first FDA-approved at-home treatment for molluscum contagiosum demonstrates effective market penetration in an area of unmet medical need, aligning with successful niche market strategies seen in other specialized pharmaceutical companies.
• The anticipated generic competition for Evomela (Teva in 2026) and Kyprolis (Breckenridge in 2027 or sooner) highlights the inherent patent cliff risks prevalent across the pharmaceutical industry, which Ligand aims to offset through its broad and continuously expanding royalty portfolio.

Management Changes

Corporate Governance

Legal Proceedings

• In Re: National Prescription Opiate Litigation: Three civil complaints filed in U.S. District Court for the Northern District of Ohio on October 31, 2019, on behalf of several Indian tribes. Allegations focus on other defendants, with no individualized factual allegations against Ligand. The company rejects all claims and intends to vigorously defend.
• CyDex Pharmaceuticals, Inc. vs. Bexson Biomedical, Inc.: CyDex filed a Verified Complaint in Delaware Court of Chancery on August 22, 2024, alleging breach of a Captisol In Vivo Agreement, misuse of confidential information, and filing of infringing patent applications. Bexson filed a Verified Counterclaim, Answer, and Affirmative Defenses on May 23, 2025. Oral argument on pending motions for judgment on the pleadings is scheduled for April 22, 2026.
• Baxter and CyDex vs. PH Health Ltd. et al.: A lawsuit was filed in the U.S. District Court for the District of New Jersey on August 29, 2025, asserting infringement of U.S. Patent No. 7,635,773 related to Nexterone by PH Health's ANDA filing. Discovery has started, but a trial date has not yet been set.
• Evomela Patent Litigation: CyDex and Acrotech previously settled litigations. In 2025, they filed suit against Gland Pharma Limited for infringing three Orange Book-listed patents related to Evomela. The latest asserted patent expires in May 2030. An Answer has not yet been filed.
• Kyprolis Patent Litigation: Amgen filed suit against several generic drug companies. Settlements with some parties are confidential, but a U.S. launch date for at least Breckenridge Pharmaceuticals' generic product is publicly reported for 2027 or sooner. Cipla Limited/Cipla USA, Inc. proceeded to trial, and the District Court upheld the validity of patent claims, which was upheld on appeal.

Related Party Transactions

• Pelthos Therapeutics Inc. is considered a related party due to Ligand's significant equity interest (approximately 48% of common stock and 60% of Series A convertible preferred stock) and ongoing contractual arrangements.
• Ligand's CEO and director, Todd Davis, and Senior Vice President of Investment Operations, Richard Baxter, were appointed to Pelthos' board of directors following the Pelthos Transaction. Todd Davis recused himself from both boards' consideration and approval of the Pelthos Transaction.
• Ligand invested $18 million in Pelthos as part of a $50 million equity private placement.
• Ligand invested $9 million in Pelthos private convertible notes financing.
• Former President and Chief Operating Officer Matt Korenberg served as a board member of Primrose Bio, and Lauren Hay, Vice President of Strategic Planning & Investment Analytics, succeeded him.

Stakeholder Impact

• Shareholders: Experience positive impact from significant revenue and net income growth, increased cash position, and strategic investments. Potential for dilution exists from 2030 Notes conversion and warrants. The stock repurchase program could benefit shareholders, but stock price volatility remains a risk.
• Employees: Benefit from competitive pay, recognition, and comprehensive benefits packages including equity awards, health insurance, 401(k) matching, tuition assistance, and paid time off. The company fosters a flexible work environment and promotes diversity initiatives.
• Customers/Partners: Receive continued support through capital deployment and technology licensing. The success of partnered products like Zelsuvmi, D-Fi, AVIM Therapy, and Virtue SAB directly benefits partners. Risks include potential supply interruptions for Captisol and partner insolvency.
• Creditors: The issuance of $460 million convertible senior notes increases debt. The Revolving Credit Facility provides liquidity but imposes covenants. Obligations under the Credit Agreement are secured by certain collateral.
• Regulatory Bodies: The company and its partners are subject to extensive FDA and other governmental regulations, requiring ongoing compliance. Potential for delays in regulatory approvals or enforcement actions for non-compliance exists.

Next Steps

• NDA submission for Qtorin rapamycin planned for the second half of 2026.
• Palvella plans to meet with the FDA in the first half of 2026 to discuss the proposed design of a Phase 2 study to evaluate Qtorin rapamycin for the treatment of clinically significant angiokeratomas.
• Renalys (Chugai) plans to submit an NDA for Filspari in Japan in 2026.
• FDA PDUFA target action date for Filspari sNDA for FSGS is April 13, 2026.
• Oral argument on the CyDex vs. Bexson lawsuit is scheduled to occur on April 22, 2026.
• The company expects to continue efforts and refine EHS policies and practices in 2026.
• The company expects to continue proactive shareholder and employee engagement in 2026.
• The company expects to acquire shares under the $50 million stock repurchase program through April 2026.
• Results from the BEACON-2 trial for Qarziba are expected in 2028.
• Data from Phase 3 ELAINE-3 clinical trial for Lasofoxifene expected in mid-2027.

Key Dates

Recommendation

Ligand Pharmaceuticals demonstrates exceptional financial performance in FY2025 with a 60% increase in total revenue and a substantial return to net income. The company's focused royalty aggregation strategy is proving highly effective, generating diversified, high-margin cash flows. Key product royalties are growing, and strategic investments in late-stage assets like D-Fi, AVIM Therapy, and Virtue SAB, along with the successful Pelthos Transaction, position the company for continued future growth. While generic competition for some products and increased R&D expenses are noted, the strong balance sheet, significant cash reserves, and a robust pipeline of royalty-generating assets make it a compelling "Strong Buy" for long-term investors seeking exposure to diversified biopharmaceutical innovation with mitigated development risk.

Keywords

Biopharmaceutical, Royalty company, SEC filing, 10-K, Financial results, Captisol, NITRICIL, Zelsuvmi, Pelthos, Kyprolis, Filspari, Ohtuvayre, Capvaxive, D-Fi, Orchestra BioMed, Arecor, Agenus, Viking Therapeutics, Lasofoxifene, Drug development, Intellectual property, Corporate governance, Risk management, Investments, Convertible notes, Share repurchase